Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | MAX | P61244 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 5/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811891 | 1.00 | AURKA (0.39) | AURKABDKRB1CNR2MYCMAX | |
| SCHEMBL2805157 | 0.91 | AURKA (0.39) | AURKABDKRB1MYCMAXMAPK9 | |
| SCHEMBL2805158 | 0.91 | AURKA (0.39) | AURKABDKRB1MYCMAXMAPK9 | |
| SCHEMBL2806967 | 0.91 | AURKA (0.39) | AURKABDKRB1CNR2MYCMAX | |
| SCHEMBL2806970 | 0.91 | AURKA (0.39) | AURKABDKRB1CNR2MYCMAX | |
| SCHEMBL2811098 | 0.89 | NAMPT (0.41) | AURKABDKRB1MYCMAX | |
| SCHEMBL2811096 | 0.89 | NAMPT (0.41) | AURKABDKRB1MYCMAX | |
| SCHEMBL2808667 | 0.89 | BDKRB1 (0.40) | AURKABDKRB1CNR2MYCMAX | |
| SCHEMBL2808664 | 0.89 | BDKRB1 (0.40) | AURKABDKRB1CNR2MYCMAX | |
| SCHEMBL2808646 | 0.88 | HDAC1 (0.42) | AURKABDKRB1CNR2MYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | AURKA 3494/4885BDKRB1 289/4885CNR2 882/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | AURKA 3494/4885BDKRB1 289/4885CNR2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.